N-terminal pro-brain natriuretic peptide in systemic lupus erythematosus: Relationship with inflammation, augmentation index, and coronary calcification

Journal of Rheumatology

Volumn 35, Issue 7, 2008, Pages 1314-1319

  Chung, Cecilia P ^a,b   Solus, Joseph F ^b   Oeser, Annette ^a   Avalos, Ingrid ^a   Kurnik, Daniel ^a   Raggi, Paolo ^c   Stein, C Michael ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; N terminal pro brain natriuretic peptide; Systemic lupus erythematosus

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTERY CALCIFICATION; ARTICLE; AUGMENTATION INDEX; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; DISEASE DURATION; ELECTRON BEAM TOMOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

CALCINOSIS; CASE-CONTROL STUDIES; COLONOGRAPHY, COMPUTED TOMOGRAPHIC; CORONARY ARTERY DISEASE; ELASTICITY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PULSATILE FLOW;

EID: 47349103299     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
2. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
3. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
4. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-63.
5. McKie PM, Rodeheffer RJ, Cataliotti A, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 2006;47:874-80.
6. Abdullah SM, Khera A, Das SR, et al. Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of N-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study). Am J Cardiol 2005;96:1284-9.
7. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
8. Urowitz MB, Gladman DD. Late mortality in SLE - "the price we pay for control". J Rheumatol 1980;7:412-6.
9. Asanuma Y, Oeser A, Shintani AK. et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Eng J Med 2003;349:2407-15.
10. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Eng J Med 2003;349:2399-406.
11. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
12. Chung CP, Oeser A, Avalos I, Raggi P, Stein CM. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 2006;15:562-9.
13. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
14. Asanuma Y, Chung CP, Oeser A, et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006;33:539-45.
15. Oeser A, Chung CP, Asanuma Y, Avalos I, Stein CM. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum 2005;52:3651-9.
16. Turner E, Dishy V, Chung CP, et al. Endothelial function in systemic lupus erythematosus: relationship to disease activity, cardiovascular risk factors, corticosteroid therapy and coronary calcification. Vasc Health Risk Manag 2005;1:357-60.
17. Chung CP, Avalos I, Oeser A, et al. High frequency of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007;66:208-14.
18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
19. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
20. Levey AS, Greene T, Kusek J, Beck GA. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol 2000;11:155A.
21. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Vaimonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827-32.
22. Wilkinson IB, Fuchs SA, Jansen IM, et al. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens 1998;16:2079-84.
23. Karadag O, Calguneri M, Yavuz B, et al. B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: what is the clinical significance? Clin Rheumatol 2007;26:1701-4.
24. Magga J, Marttila M, Mantymaa P, Vuolteenaho O, Ruskoaho H. Brain natriuretic peptide in plasma, atria, and ventricles of vasopressin- and phenylephrine-infused conscious rats. Endocrinology 1994;134:2505-15.
25. Hall C. NT-ProBNP: the mechanism behind the marker. J Card Fail 2005;11 Suppl:S81-S83.
26. Bruneau BG, Piazza LA, de Bold AJ. BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. Am J Physiol 1997;273:H2678-86.
27. Goetze JP, Christoffersen C, Perko M et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003;17:1105-7.
28. Casco VH, Veinot JP, Kuroski de Bold ML, Masters RG, Stevenson MM, de Bold AJ. Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem 2002;50:799-809.
29. Wang TJ, Larson MG, Levy D, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002;90:254-8.
30. Michos ED, Vasamreddy CR, Becker DM, et al. Women with a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis. Am Heart J 2005;150:1276-81.
31. Michos ED, Nasir K, Braunstein JB, et al. Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Atherosclerosis 2006;184:201-6.
32. Dawson A, Davies JI, Morris AD, Struthers AD. B-type natriuretic peptide is associated with both augmentation index and left ventricular mass in diabetic patients without heart failure. Am J Hypertens 2005;18:1586-91.
33. Roman MJ, Devereux RB, Schwartz JE, et al. Arterial stiffness in chronic inflammatory diseases. Hypertension 2005;46:194-9.
34. Rudiger A, Gasser S, Fischler M, Hornemann T, von Eckardstein A, Maggiorini M. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med 2006;34:2140-4.
35. Brueckmann M, Huhle G, Lang S, et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005;112:527-34.
36. Ortega O, Gallar P, Munoz M, et al. Association between C-reactive protein levels and N-terminal pro-B-type natriuretic peptide in pre-dialysis patients. Nephron Clin Pract 2004;97:c125-30.
37. Raymond I, Groenning BA, Hildebrandt PR, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89:745-51.